earli
decemb
epidem
pneumonia
caus
novel
coronaviru
infect
later
name
record
citi
wuhan
hubei
provinc
china
viral
infect
soon
spread
wide
across
china
feb
case
confirm
includ
healthcar
worker
death
estim
mortal
rate
china
compar
mortal
rate
middl
east
respiratori
syndrom
merscov
sever
acut
respiratori
syndrom
sarscov
urgent
novel
coronaviru
spread
across
globe
affect
countri
case
confirm
outsid
china
relat
death
record
particularli
abrupt
speed
outbreak
japan
iran
korea
itali
late
februari
indic
global
catastroph
unfold
great
concern
virus
coronavirida
famili
possess
singlestrand
positivesens
rna
identifi
variou
avian
host
mammal
seven
could
caus
ill
rang
common
cold
sever
diseas
merscov
sarscov
new
coronaviru
previous
identifi
similar
coronaviru
respons
sarscov
sequenc
ident
distant
merscov
homolog
coronavirus
includ
least
three
structur
protein
share
membran
spike
membran
protein
small
membran
protein
e
also
anoth
four
function
protein
found
almost
coronavirus
proteas
papainlik
proteas
plpro
rnadepend
rna
polymeras
rdrp
helicas
viral
infect
process
includ
intracellular
transport
virion
prolifer
assembl
virion
infect
cellnot
structur
function
protein
also
proteas
play
key
part
suggest
target
protein
enzym
therapi
infect
could
promis
strategi
date
special
drug
vaccin
use
deal
human
coronavirus
consid
serious
sudden
outbreak
clinic
trial
commenc
china
promis
report
certain
target
agent
display
strong
antivir
potenti
permit
use
attempt
combat
diseas
clinic
trial
remdesivir
favipiravir
interfer
synthesi
viral
mrna
target
rdrp
remdesivir
develop
gilead
monophosphoramid
prodrug
intend
intraven
treatment
ebola
also
show
potenti
coronaviru
nipah
viru
infect
result
evalu
antivir
effici
remdesivir
clinic
isol
vitro
suggest
could
inhibit
strongli
ec
rang
mm
remdesivir
cure
first
case
infect
confirm
usa
prompt
gilead
chines
author
move
phase
iii
trial
ahead
expand
lot
patient
desper
need
treatment
final
result
clinic
trial
announc
april
contrast
remdesivir
activ
report
favipiravir
vitro
vivo
limit
howev
still
three
activ
clinic
trial
regard
favipiravir
begun
enrol
patient
china
lopinavir
ritonavir
target
use
treat
sar
patient
china
shortli
emerg
merscov
research
identifi
lopinavir
ritonavir
merscov
inhibitor
nation
expert
group
recommend
lopinavir
ritonavir
effect
agent
china
clinic
trial
select
drug
posit
control
emtricitabin
tenofovir
alafenamid
revers
transcriptas
inhibitor
approv
treat
hiv
hepat
b
viru
hbv
current
one
trial
combin
emtricitabin
tenofoviralafenamid
lopinavirritonavir
treat
patient
arbidol
oligoadenyl
synthesi
oa
inhibitor
sever
pneumonia
virusassoci
cytokin
dysregul
display
potenti
clinic
trial
howev
mechan
need
clarifi
near
futur
chloroquin
deriv
includ
hydroxychloroquin
chloroquin
phosphat
elicit
antivir
effect
sever
virus
sarscov
interf
endosom
acidif
base
advantag
known
broadspectrum
activ
rare
occur
advers
reaction
seri
clinic
trial
chloroquin
deriv
advanc
rapidli
present
chines
govern
author
approv
chloroquin
phosphat
use
treat
adult
patient
suffer
infect
treatment
combin
tradit
chines
medicin
tcm
chemic
molecul
popularli
known
western
medicin
china
shown
excit
result
view
inconclus
clinic
evid
tcm
efficaci
pharmacologist
separ
activ
pharmaceut
ingredi
identifi
explicit
target
soon
possibl
surprisingli
variou
drug
also
clinic
trial
despit
lack
biolog
rational
antiinfluenza
drug
umifenovir
oseltamivir
target
neuraminidas
baloxavirmarboxil
target
capdepend
endonucleas
found
target
proteas
anticoronaviru
research
report
cobicistat
target
unpersuas
predict
activ
comput
virtual
dock
crystal
structur
spike
dimer
fulllength
human
receptorbind
domain
bound
receptor
publish
success
lead
drug
discoveri
strategi
structurebas
ht
molecular
dynam
simul
discov
inhibitor
affin
protein
proteinprotein
interact
possibl
near
futur
three
major
outbreak
coronavirus
centuri
sarscov
merscov
draw
experi
effect
screen
strategi
antitumor
drug
develop
credibl
largescal
screen
system
especi
deadli
coronavirus
must
set
molecular
level
anim
model
soon
possibl
although
clinic
safeti
old
drug
proven
caus
seriou
advers
reaction
exampl
hydroxychloroquin
side
effect
arrhythmia
lead
death
thu
special
attent
need
paid
safeti
old
drug
new
indic
drug
display
potent
inhibitori
effect
viru
vitro
vivo
howev
mechan
unclear
exist
theori
explain
phenomenon
moreov
basic
research
effort
devot
molecular
mechan
separ
andor
purif
anoth
disturb
fact
unreason
clinic
trial
scheme
consum
preciou
patient
resourc
other
even
approv
ethic
committe
clinic
trial
must
undertaken
activ
care
scientif
reflect
basic
principl
helsinki
declar
relev
law
regul
despit
urgenc
gener
emerg
new
coronaviru
research
maintain
rigor
evid
follow
guidelin
clinic
trial
statist
basic
principl
includ
random
control
repetit
first
harm
still
top
prioriti
